Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

COVID-19 and managing metabolic risk

Identifying metabolic risk is key in optimizing patient outcomes

A recent study published in the journal Diabetes Care links metabolic syndrome and severe outcomes from COVID-19, noting significant increases in intensive-care admissions, ventilation, acute respiratory distress syndrome (ARDS), and death among patients with metabolic syndrome vs those without metabolic syndrome.1

Deferred medical care is a continuing, alarming trend

Delaying care due to the COVID-19 pandemic may be increasing deaths for many conditions, including diabetes. Diabetes deaths rose to nearly 25% per 100,000 in 2020, the largest rise in the diabetes death rate in decades.2

Stay ahead of metabolic syndrome with enhanced diagnostic insights

Quest Diagnostics provides advanced testing to help you assess and care for patients with underlying metabolic risk.

Metabolic syndrome is defined by the National Heart, Lung, and Blood Institute as a group of factors increasing risk for heart disease, diabetes, stroke, and other health problems. Patients are said to have metabolic syndrome if they have 3 or more of the following conditions4:


Obesity (BMI ≥30)


High levels of triglycerides


High blood pressure


Diabetes or prediabetes


Low levels of high-density

lipoprotein (HDL-C)

Cardiometabolic testing for at-risk patients

There are a variety of testing approaches for metabolic risk based on the needs of individual patients. The chart below lists some of the tests Quest offers to help you power better patient outcomes.

Test name Test code CPT code(s)
Cardio IQ® Hemoglobin A1c
Includes Insulin, Intact, LC/MS/MS (93103), C-Peptide (372), Insulin Resistance Score		 91732 83036
Diabetes, Newly Diagnosed and Monitoring Panela
Includes Glucose (483), HbA1c (496), Albumin-Creatinine Ratio, Urine (92739), Creatine, Serum (37091); Lipid Panel (7600) which includes Cholesterol, Total (334), Triglycerides (896), HDL Cholesterol (608), LDL-Cholesterol (calculated), Cholesterol/HDL Ratio (calculated), Non-HDL Cholesterol (calculated); Hepatic Function Panel (10256) which includes Protein, Total, Serum (754), Albumin (223), Globulin (calculated), Albumin/Globulin Ratio (calculated), Bilirubin, Total (287), Bilirubin, Direct (285), Indirect Bilirubin (calculated), Alkaline Phosphatase (234), Aspartate Aminotransferase (AST) (822), Alanine Aminotransferase (ALT) (823)		 91712 82947, 83036,
80061, 80076,
82570, 82043,
82565

aPanel components may be ordered separately.

Testing for insulin resistance (IR) can help patients take action

IR affects more than 60 million Americans.5 Testing can provide insights that can help patients prevent or delay the course of their prediabetes/diabetes.6

Comprehensive testing gives you better insights

Patients can have normal glucose and HbA1c, but their beta cells may be struggling with glucose load, leading to IR and subsequently, prediabetes and diabetes

Symptoms aren’t always obvious

IR can be gradual and difficult to recognize6—but patients can be identified  when there’s still time to change course

IR is tied to other metabolic conditions

IR is associated with cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS)6
Test name Test code CPT code(s)
Cardio IQ® Insulin Resistance Panel with Scorea
Includes Insulin, Intact, LC/MS/MS (93103), C-Peptide (372), Insulin Resistance Score		 36509 83525, 84681


aPanel components may be ordered separately

Metabolic conditions and complications from

SARS-CoV-2 (COVID-19) infections

View our brochure to learn more about improving patient outcomes

through metabolic risk testing.

Download

References

  1. Xie J, Zu Y, Alkhatib A, et al. Metabolic syndrome and COVID-19 mortality among adult black patients in New Orleans [published online ahead of print August 25, 2020]. Diabetes Care. doi:10.2337/dc20-1714
  2. Stobbe M. US deaths from heart disease and diabetes climbed amid COVID. Associated Press. June 9, 2021. Accessed June 10, 2021. https://apnews.com/article/coronavirus-pandemic-diabetesscience-heart-diseasehealth-213fe132f33c9428ea39274ffb96aa01
  3. American Diabetes Association, Thrivable. Effects of the COVID-19 pandemic on people with diabetes. December 2020 survey summary report. Accessed June 4, 2021. https://www.diabetes.org/sites/default/files/2020-12/ADA%20Thrivable%20Data%20Deck.pdf
  4. National Heart, Lung, and Blood Institute (NIH). Metabolic syndrome. Accessed October 1, 2020. https://www.nhlbi.nih.gov/health-topics/metabolic-syndrome
  5. American Heart Association (AHA). What is diabetes? Reviewed August 30, 2015. Accessed October 1, 2020. https://www.heart.org/en/health-topics/diabetes/about-diabetes
  6. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep. 2003;5(5):364-371. doi:10.1007/s11883-003-0007-0


The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

 

Test codes may vary by location. Please contact your local laboratory for more information.

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More

Metabolic Risk & COVID-19

Resources

About our tests: Cardiovascular disease

4myheart® program

For your team: A treatment guide to lipid disorders

How to read your patient’s Cardio IQ® report

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.